Antibodies
15 September 2024
OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates15 September 2024
Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 202415 September 2024
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases15 September 2024
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia13 September 2024
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy12 September 2024
Radiant Bio Closes $35 Million Series A Financing to Advance Therapeutic Pipeline with Its Proprietary Multabody™ Platform12 September 2024
Depemokimab late-breaking data presented at ERS show a 54% reduction in severe asthma exacerbations12 September 2024
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU12 September 2024
IGI Announces Publication in Nature Cancer on ISB 2001, IGI’s Innovative Trispecific Antibody for Relapsed/Refractory Multiple Myeloma10 September 2024
AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs10 September 2024
Phanes Therapeutics Announces First Patient Dosed in Clinical Study of PT886 in Combination with ChemotherapyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports